VC Bob Nelsen argues that even if large pharma companies appropriate ideas or gain leverage over US biotech, their financial success is ultimately beneficial. Profitable pharma companies must deploy massive cash reserves, much of which flows back into the biotech ecosystem through M&A, funding the next generation.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Ipsen views its R&D strategy as accelerating innovation sourced from academia and biotech. It leverages its strengths in clinical, regulatory, and commercialization to complement the focused discovery work done by smaller partners, acting as a catalyst within the broader life sciences ecosystem rather than just a buyer.

Responding to Wall Street pressure to de-risk, large pharmaceutical firms cut internal early-stage research. This led to an exodus of talent and the rise of contract research organizations (CROs), creating an infrastructure that, like cloud computing for tech, lowered the barrier for new biotech startups.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

Dr. Saav Solanki observes that many breakthrough medicines don't follow a linear path within one organization. Instead, they are developed collaboratively, often starting in a university lab, moving to a small biotech for initial development, and finally being acquired or licensed by a large pharma company for commercialization.

ProPhet was founded through Ion Labs, a venture studio created by AstraZeneca, Merck, Pfizer, and Teva. This model allows established pharmaceutical giants to identify acute internal challenges and recruit external talent to build dedicated startups aimed at solving them.

Lyora Therapeutics' model is built on acquiring promising, pre-clinically validated programs that larger companies shelved due to strategic shifts. This "asset-driven" approach allows a new company to rapidly build a pipeline without the cost and time of early-stage discovery, capitalizing on the sunk R&D costs of former owners.